Please login to the form below

Not currently logged in
Email:
Password:

Swiss biotech Inositec appoints new chief medical officer

Dr Frits van Alphen joins the group from Roche

Zurich-based biotechnology company Inositec has appointed a new chief medical officer in the form of Dr Frits van Alphen.

He said: “As CMO of Inositec, I have the golden opportunity to utilise my broad experience and entrepreneurial mind-set to develop new medicines.

“These innovative products have the potential to significantly advance patient care in vascular and other calcification disorders, all with high unmet medical need.”

Dr van Alphen joins from Roche, where he headed its operational excellence team and prior to this he was chief medical officer at Vifor Pharma, head of medical affairs Europe at Novartis as well as heading their clinical operations team in the Netherlands.

Dr Mattias Ivarsson, chief medical officer of Inositec, said: “Dr van Alphen is a key addition to Inositec’s team as we enter IND/CTA-enabling studies with out lead programme in the vascular calcification space and fine-tune our clinical strategy in view of first-in-human studies in 2019.”

23rd January 2018

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...